Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
Not yet recruiting · NCT06858722 · Registry updated 2025-03-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Not yet recruiting | Phase 3 | 2025-03-05 | NCT06858722 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhongming Qiu | 11 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||